While not typically found in healthy brain cells, non-mutated EGFR is frequently expressed by glioblastoma cells. The INCIPIENT trial was a phase 1 study designed to test the safety and potential ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

Clinical studies of proton therapy have been performed for several types of tumors, including gliomas. [64] Fitzek et al. conducted a Phase II study of 23 GBM patients treated with radiation dose ...

Just three patients were recruited, all diagnosed with a form of glioblastoma expressing the variant EGFR. The first patient, a 74 year old man, had undergone standard medication and radiation ...

EGFR-positive lung cancer is a type of non-small cell lung cancer (NSCLC). It can cause symptoms such as breathing problems and hoarseness. Therapy that targets the mutation, such as EGFR ...

The glioma tumors from 17 individuals (with an average fire-fighting history of 22 years) were compared with those from 18 individuals in non-firefighting occupations.

The epidermal growth factor receptor (EGFR) is a target found in high concentrations ... A phase 2 trial of gefitinib in first-relapse glioblastoma multiforme demonstrated median overall survival ...

“We also look forward to the expansion in the first quarter of 2025 of the investigator sponsored window of opportunity trial of BDTX-1535 into newly diagnosed glioblastoma patients with EGFR ...

Black Diamond ended 2024 with approximately $98.6M in cash, cash equivalents, and investments compared to $131.4M as of December 31, 2023. Net ...